Liver injury caused by antiviral agents for COVID-19.
Chinese Journal of Clinical Infectious Diseases
; 13(2):102-108, 2020.
Article
in Chinese
| EMBASE | ID: covidwho-2287563
ABSTRACT
Antiviral therapy is important for COVID-19. Currently, the anti-2019-nCoV drugs in clinical trials include broad-spectrum antiviral drugs (alpha interferon and ribavirin), hemagglutinin inhibitors (arbidol), human immunodeficiency virus protease inhibitors (lopinavir/ritonavir and darunavir/cobicistat), nucleoside analogues (favipiravir and remdesivir) and antimalarial drug (chloroquine);while liver damage may occur in some patients with the medication. This article reviews the research on liver damage associated with anti-2019-nCoV drugs, aiming at promoting the safe and effective antiviral therapy for COVID-19 patients.Copyright © 2020 by the Chinese Medical Association.
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
Chinese
Journal:
Chinese Journal of Clinical Infectious Diseases
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS